KIT and acute myeloid leukemia: Although only exon 17 mutations in KIT have been established as a poor prognostic factor in RUNX1::RUNX1T1-AML (30), other KIT activating mutations may also serve as potential molecular targets for AML treatment, particularly in relapsed cases (31).